

28th November 2018

Dear Healthcare Professional,

Notification of supply issue for Bricanyl[®] Turbohaler[®] 0.5mg/dose, inhalation powder (terbutaline sulfate).

I am writing to inform you that AstraZeneca is currently experiencing a temporary interruption in the supply of Bricanyl[®] Turbohaler[®] (terbutaline sulfate) to the United Kingdom. There will be interim deliveries of this medicine in late November and in December; however, normal stock levels are not expected until the end of January 2019.

Bricanyl[®] Turbohaler[®] is a selective beta₂-adrenergic agonist recommended for the relief and prevention of bronchospasm in bronchial asthma and other bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor.

We recommend that patients who require, but are unable obtain Bricanyl[®] Turbohaler[®] supply, are assessed by a healthcare professional and provided with an alternative treatment in an appropriate device. There is no directly substitutable product for Bricanyl[®] Turbohaler[®]; however, there are alternative products in the same class of drug. Short-acting β₂-adrenergic agonists (SABAs) with a similar mode of action like salbutamol (Ventolin Evohaler, Ventolin Accuhaler, Easyhaler, Salamol Easi-breathe) should be considered as alternatives following individual patient assessment.

Please note that differences in indication, posology, administration and device may exist for the alternative therapies.

We are sorry for the inconvenience and disruption caused to your patients and yourself. If you have any questions relating to the supply of this medicine, please call AstraZeneca Supply Chain Team on 0800 032 0501 or email at: supply.chain@astrazeneca.com

For other information regarding the medicine, please call AstraZeneca Medical Information on 0800 783 0033 or email at: medical.informationUK@astrazeneca.com

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033.

Yours faithfully,



Dr Dilruwan Herath
Medical and Regulatory Affairs Director, AstraZeneca UK